1. Introduction {#sec1-jcm-09-02051}
===============

Cardiogenic shock (CS) is a low cardiac output state that leads to hypoperfusion and subsequent multi-organ failure with high mortality rates \[[@B1-jcm-09-02051],[@B2-jcm-09-02051]\]. The commonly used clinical definition of CS is based on hemodynamic criteria and signs of hypoperfusion \[[@B3-jcm-09-02051]\].

Vasopressors and inotropes are routinely used in the treatment of CS to improve hemodynamics and restore organ perfusion. Scientific statements recommend noradrenaline as the first-line pharmacologic treatment strategy in CS, with the addition of inotropes in patients with persistent low cardiac output \[[@B4-jcm-09-02051],[@B5-jcm-09-02051]\].

Acute myocardial infarction (AMI) is a common cause of CS, accounting for at least 30% of the cases \[[@B6-jcm-09-02051],[@B7-jcm-09-02051],[@B8-jcm-09-02051]\]. Vasopressors and inotropes are used in patients with AMI related CS, in the assumption that they improve and maintain adequate coronary perfusion and cardiac output. However, these drugs are also associated with arrhythmias and may increase the myocardial oxygen demand by increasing the contractility, afterload and/or by reducing coronary perfusion \[[@B9-jcm-09-02051]\].

Therefore, we performed a systematic review to examine the current evidence on the effect of different vasopressors and inotropes on mortality in patients with AMI related CS.

In this systematic review and meta-analysis, we addressed the following questions: (1) Is treatment with adrenaline, noradrenaline, vasopressin, milrinone, levosimendan, dobutamine or dopamine associated with reduced mortality in patients with AMI related CS? and (2) What is the effect of these drugs on complications and safety outcomes (e.g., duration of supportive measures, length of intensive care unit (ICU) stay, hemodynamic effects, organ failure and therapy-related complications)?

2. Experimental Section {#sec2-jcm-09-02051}
=======================

This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis PRISMA guidelines. \[[@B10-jcm-09-02051]\] The protocol was registered in the PROSPERO database (CRD42018107644).

2.1. Selection Criteria {#sec2dot1-jcm-09-02051}
-----------------------

To qualify for inclusion, studies must have reported on mortality in CS patients and include patients with AMI. Furthermore, studies were considered for inclusion if outcome data were reported in (A) patients treated with an inotrope or vasopressor and (B) a control group that was not exposed to the (same) inotrope or vasopressor therapy. The following inotropes and vasopressors were included: (1) adrenaline, (2) noradrenaline, (3) vasopressin, (4) milrinone, (5) levosimendan, (6) dobutamine and (7) dopamine. Studies comparing different dosages of inotropes or vasopressors were excluded, unless an unexposed control arm (B) was present. We excluded studies that reported only on post-cardiac surgery patients. We expected very few evidences from randomized controlled trials (RCTs) and therefore we included all study designs except case reports and correspondences.

2.2. Search Strategy {#sec2dot2-jcm-09-02051}
--------------------

A medical information specialist (JL) conducted a systematic search of the following databases: MEDLINE (OVID), EMBASE (OVID), and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception to 20 February 2019. The search included both controlled terms (i.e., MeSH-terms) and free-text words for: (1) cardiogenic shock (or shock /low cardiac output and MI) and (2) inotrope/vasopressor drugs (see [Appendix A](#app2-jcm-09-02051){ref-type="app"}). Non-human studies, narrative reviews and editorials were excluded. No further restrictions were applied. Reference lists and citing articles of identified relevant papers were crosschecked. The search was adapted in the case of additional relevant studies. The bibliographic records retrieved were imported using EndNote X8 and duplications were removed.

2.3. Data Extraction and Quality Assessment {#sec2dot3-jcm-09-02051}
-------------------------------------------

Two researchers (either MK, WL, DO or VH) independently screened titles and abstracts of the retrieved papers and excluded studies based on the selection criteria. Subsequently, two researchers independently assessed the eligibility of the potentially eligible papers in full text. Conference papers were considered for inclusion if they met selection criteria and necessary data were available. After the eligible studies were identified, two researchers (MK and VH) independently performed data extraction. We attempted to retrieve unclear or missing data by contacting the corresponding authors of studies. The quality of the individual studies was assessed using the Revised Cochrane risk-of-bias (RoB 2.0) for RCTs and the Newcastle--Ottawa scale (assessed on mortality outcome level) for non-randomized studies \[[@B11-jcm-09-02051],[@B12-jcm-09-02051]\]. The overall quality of evidence was assessed using the GRADE's approach \[[@B13-jcm-09-02051]\]. Any discrepancies between the researchers were solved by discussion and/or the involvement of a third researcher (JH).

2.4. Data Analysis {#sec2dot4-jcm-09-02051}
------------------

The primary outcome was mortality, defined as short-term (\<90 day) and long-term (≥90 day) mortality. The therapy group was defined as the examined vasopressor/inotrope. The control group was constructed from the cumulated comparator of the different studies. We summarized mortality in a quantitative manner, using a random-effects model, presented with relative risks (RR) and 95% confidence intervals (CI). Heterogeneity was evaluated using Chi-squared and I-squared test, with the significance set at a *p*-value of 0.10. An I-squared test of \>40% was considered indication of substantial heterogeneity. Sensitivity analyses (excluding conference papers and/or observational studies) were applied where appropriate. Review Manager (version 5.3) was used for statistical analysis. We also provided a narrative synthesis of the included studies regarding study population, therapies and outcome(s) and described the following secondary outcomes: duration of supportive measures, length of ICU stay, hemodynamic effects, organ failure and therapy-related complications.

3. Results {#sec3-jcm-09-02051}
==========

3.1. Search Results {#sec3dot1-jcm-09-02051}
-------------------

Of the 6187 unique publications retrieved, 110 were assessed full text for eligibility and 19 studies were included in the review. The reasons for exclusion are listed in [Figure 1](#jcm-09-02051-f001){ref-type="fig"}.

3.2. Study Characteristics {#sec3dot2-jcm-09-02051}
--------------------------

Study characteristics of the 19 included studies are presented in [Table 1](#jcm-09-02051-t001){ref-type="table"}.

3.3. Participants {#sec3dot3-jcm-09-02051}
-----------------

The overall patient population included in the studies and baseline characteristics of the CS patients are described in the [Supplementary Materials, Table S1](#app1-jcm-09-02051){ref-type="app"}. In total, 4441 patients were included, of whom 2478 CS patients. All included studies included at least a subgroup with AMI related CS, and 10 studies included only patients with AMI related CS. Overall, there were 137 CS patients treated with adrenaline, 594 CS patients treated with noradrenaline, 8 CS patients treated with vasopressin, 50 CS patients treated with milrinone, 209 CS patients treated with levosimendan, 200 CS patients treated with dobutamine and 367 CS patients treated with dopamine.

3.4. Intervention {#sec3dot4-jcm-09-02051}
-----------------

Criteria for initiation of vasopressor or inotrope therapy differed amongst the various studies and are described in the [Supplementary Materials (Table S1)](#app1-jcm-09-02051){ref-type="app"}.

3.5. Comparison {#sec3dot5-jcm-09-02051}
---------------

We identified six RCTs with different comparisons \[[@B14-jcm-09-02051],[@B15-jcm-09-02051],[@B16-jcm-09-02051],[@B17-jcm-09-02051],[@B18-jcm-09-02051],[@B19-jcm-09-02051]\]; noradrenaline versus adrenaline in patients with AMI related CS (Levy, 2018), noradrenaline versus adrenaline in patients that required a vasopressor for any cause (Myburgh, 2008), noradrenaline versus dopamine in patients with shock of all-causes (De Backer, 2010 = SOAP II trial), dobutamine versus levosimendan in STEMI patients with CS after PCI (Samimi-Fard, 2007), levosimendan versus placebo in acute STEMI patients with clinical signs of heart failure \<48 h after primary PCI (Huseby, 2013 = LEAF trial) and levosimendan versus enoximone in patients with refractory CS \< 2 h after PCI (Fuhrmann, 2008). Of note, in all of the included studies, the control group was exposed to some type of vasopressor or inotrope other than the drug that was examined (noradrenaline in most cases).

3.6. Quality of Studies {#sec3dot6-jcm-09-02051}
-----------------------

The overall body of evidence regarding the primary outcome was graded low, assessed using the GRADE's approach. This grade was based on only limited evidence from randomized trials with serious inconsistency and risk of bias. The individual quality assessment of the studies is presented in the [Supplementary Materials; Table S2](#app1-jcm-09-02051){ref-type="app"} for the randomized studies and [Table S3](#app1-jcm-09-02051){ref-type="app"} for the observational studies.

3.7. Mortality Outcomes {#sec3dot7-jcm-09-02051}
-----------------------

The synthesis of mortality is shown in [Figure 2](#jcm-09-02051-f002){ref-type="fig"} for short-term mortality and [Figure 3](#jcm-09-02051-f003){ref-type="fig"} for long-term mortality. Mortality outcomes of CS patients in the individual studies are described in the [Supplementary Materials, Table S4](#app1-jcm-09-02051){ref-type="app"}.

### 3.7.1. Adrenaline vs. Constructed Control {#sec3dot7dot1-jcm-09-02051}

Three of the included studies reported on patients treated with adrenaline \[[@B14-jcm-09-02051],[@B15-jcm-09-02051],[@B20-jcm-09-02051]\]. Levy et al. and Myburgh et al. performed an RCT comparing the effect of adrenaline and noradrenaline on hemodynamic parameters (respectively, cardiac index evolution and achievement of MAP goal \> 24 h). Tarvasmaki et al. performed an observational study in which they compared 90-day mortality of patients with acute CS treated with adrenaline (also for noradrenaline, vasopressin, levosimendan, dobutamine, dopamine) versus a non-exposed control group. The two RCTs comparing adrenaline with noradrenaline evaluated 28-day mortality. Their pooled estimate showed no treatment effect of adrenaline on short-term mortality (RR 1.22, 95% CI 0.60--2.50, heterogeneity *I*^2^ = 58%). Pooled estimate of the studies that reported on long-term mortality also showed no treatment effect of adrenaline (RR 1.37 95% CI 0.45--4.16; *n* = 2 studies), with substantial heterogeneity between the studies (*I*^2^ = 94%).

### 3.7.2. Noradrenaline vs. Constructed Control {#sec3dot7dot2-jcm-09-02051}

Six studies (three RCTs) reported on patients treated with noradrenaline \[[@B14-jcm-09-02051],[@B15-jcm-09-02051],[@B16-jcm-09-02051],[@B20-jcm-09-02051],[@B21-jcm-09-02051],[@B22-jcm-09-02051]\]. Treatment with noradrenaline was not associated with a difference in short-term mortality (RR 0.84, 95% CI 0.63--1.10; *n* = 4 studies, heterogeneity *I*^2^ = 30%). Sensitivity analysis including only the three RCTs that reported on short-term mortality also showed no treatment effect of noradrenaline (RR 0.77, 95% CI 0.56--1.06; *I*^2^ = 26%). Likewise, the pooled estimate showed no treatment effect of noradrenaline on long-term mortality (RR 1.31, 95% CI 0.80-2.15; *n*= 3 studies), with substantial heterogeneity between the studies (*I*^2^ = 81%).

### 3.7.3. Vasopressin vs. Constructed Control {#sec3dot7dot3-jcm-09-02051}

Mortality outcomes of vasopressin treatment were available in one observational study \[[@B20-jcm-09-02051]\]. In this study 90 day mortality consisted of 7 deaths out of 8 patients (87.5%) treated with vasopressin, compared with 81 deaths out of 208 patients (38.9%) in the control group (RR 2.25, 95% CI 1.64--3.07).

### 3.7.4. Milrinone vs. Constructed Control {#sec3dot7dot4-jcm-09-02051}

Mortality outcomes of milrinone treatment were available in one observational study \[[@B23-jcm-09-02051]\]. Lewis showed no treatment effect of milrinone on in-hospital mortality, compared with dobutamine. There was 1 death out of 50 patients (2.0%) treated with milrinone, compared with 5 deaths out of 50 patients (10.0%) in the control group (RR 0.20, 95% CI 0.02--1.65).

### 3.7.5. Levosimendan vs. Constructed Control {#sec3dot7dot5-jcm-09-02051}

Ten studies (three RCTs) reported mortality outcomes of patients treated with levosimendan \[[@B17-jcm-09-02051],[@B18-jcm-09-02051],[@B19-jcm-09-02051],[@B20-jcm-09-02051],[@B24-jcm-09-02051],[@B25-jcm-09-02051],[@B26-jcm-09-02051],[@B27-jcm-09-02051],[@B28-jcm-09-02051],[@B29-jcm-09-02051]\]. In six studies that reported on short-term mortality, the overall trend of the pooled estimate favored levosimendan therapy over the constructed control (RR 0.69, 95% CI 0.47--1.00; participants = 352, heterogeneity *I*^2^ = 39%). In sensitivity analysis excluding the conference paper, levosimendan was associated with favorable outcome, compared to the constructed control (RR 0.61, 95% CI 0.41--0.90, *n* = 5 studies). Pooled estimate showed no treatment effect of levosimendan on long-term mortality (RR 0.90, 95% CI 0.65--1.23; studies, *n* = 5, with low heterogeneity *I*^2^ = 4%). Sensitivity analysis including only the two RCTs that reported long-term mortality showed similar results (RR 0.78, 95% CI 0.36--1.70; *n* = 3 studies). We also performed additional sensitivity analysis for long-term mortality excluding only the conference paper (RR 0.95, 95% CI 0.65--1.40, *n* = 4 studies).

### 3.7.6. Dobutamine vs. Constructed Control {#sec3dot7dot6-jcm-09-02051}

Five studies (one RCT) reported on patients treated with dobutamine \[[@B17-jcm-09-02051],[@B20-jcm-09-02051],[@B23-jcm-09-02051],[@B30-jcm-09-02051],[@B31-jcm-09-02051]\]. Pooled estimate showed no treatment effect of dobutamine on short-term mortality (RR 1.84, 95% CI 0.43--7.92, substantial heterogeneity *I*^2^ = 56%). Likewise, the pooled estimate of studies that reported on long-term mortality showed no treatment effect of dobutamine (RR1.13, 95% CI 0.66--1.93; *n* = 3 studies, low heterogeneity *I*^2^ = 19%).

### 3.7.7. Dopamine vs. Constructed Control {#sec3dot7dot7-jcm-09-02051}

Four studies (one RCT) reported on patients treated with dopamine \[[@B16-jcm-09-02051],[@B20-jcm-09-02051],[@B22-jcm-09-02051],[@B32-jcm-09-02051]\]. Three studies (one RCT) reported short-term mortality. The pooled estimate showed no treatment effect of dopamine (RR 1.01 95% CI 0.65--1.57, substantial heterogeneity *I*^2^ = 84%). Sensitivity analysis without the conference paper showed similar results (RR 1.04, 95% CI 0.51--2.12; *n* = 2 studies). There was also no treatment effect of dopamine on long-term mortality (RR 0.94, 95% CI 0.81--1.10; *n*= 2 studies, low heterogeneity *I*^2^ = 0%).

3.8. Secondary Outcomes {#sec3dot8-jcm-09-02051}
-----------------------

We summarized the primary endpoint, results and secondary outcomes from the included studies in [Table S5, Supplementary Materials](#app1-jcm-09-02051){ref-type="app"}. Data on adverse events and safety outcomes were not always available in the studies, but arrhythmic events were reported frequently.

4. Discussion {#sec4-jcm-09-02051}
=============

In the present article, we reviewed the current evidence on outcomes of vasopressors and inotropes in patients with AMI related CS and found that adrenaline, noradrenaline, milrinone, levosimendan, dobutamine and dopamine were not associated with a difference in short-term or long-term mortality. The quality of the evidence was low as studies were mostly observational, heterogeneous and included a small number of patients.

We found a positive trend in the pooled estimate of six studies reporting on short-term mortality toward treatment with levosimendan (RR 0.69, 95% CI 0.47--1.00, low-level of evidence). Vasopressin was associated with a difference in long-term mortality in favor of the control group. However, this was based on the results of one observational trial including 8 CS patients treated with vasopressin, compared with a much larger control group. These results are highly biased since the study had a small sample size, was non-randomized and did not adjust for baseline differences.

Our results extend a 2018 Cochrane review with a smaller size (including 13 RCTs; 2001 participants) \[[@B33-jcm-09-02051]\]. The scope of this review was significantly different from ours, since the majority of the included patients had acute on chronic heart failure or cardiac surgery complicated by low cardiac output syndrome (LCOS) or CS, instead of AMI related CS. In this review the effect of inotropes and vasodilators on mortality in patients with LCOS or CS was evaluated, demonstrating low-quality evidence that suggested a short-term mortality benefit of levosimendan compared with dobutamine. None of the other examined inotropes or vasodilators were associated with differences in mortality.

Furthermore, a previous Cochrane review published in 2016, investigated vasopressor therapy for hypotensive shock of all etiologies (mostly septic patients) \[[@B34-jcm-09-02051]\]. Again, in this review patients with AMI related CS were underrepresented and there was no subgroup analysis performed according to shock type. Although none of the vasopressors in this review was associated with a difference in mortality, dopamine significantly increased the risk for arrhythmias compared to noradrenaline.

The ESC 2017 Guidelines for the management of AMI in patients presenting with ST-segment elevation recommend dobutamine as the initial therapy in predominant low cardiac output (Class IIb) \[[@B5-jcm-09-02051]\]. Noradrenaline is recommended in CS and severe hypotension (Class IIb) based on one study (De Backer et al.) reporting a lower rate of arrhythmias and a trend toward lower mortality compared with dopamine in a subgroup analysis \[[@B16-jcm-09-02051]\]. However, there are some methodological concerns regarding this trial since randomization was not stratified and the test for subgroup differences (*p* = 0.87) suggested that the effect was not significant. Also, the subgroup of CS patients was heterogeneous, consisting of AMI, chronic heart failure and post-cardiotomy patients. A recently published RCT examined reduced exposure to noradrenaline through permissive hypotension (lower MAP target) in patients with vasodilatory hypotension aged 65 year or older and found that reduced noradrenaline was not harmful and might even be beneficial \[[@B35-jcm-09-02051]\].

Despite the lack in evidence showing efficacy of treatment with vasopressors and inotropes in AMI related CS, there is a widespread use in clinical practice. Physicians are unlikely to refrain from the use of any vasopressor or inotrope in patients with CS. Of note, none of the included studies in this review had a control group that did not receive any vasopressor or inotrope. Therefore, the current literature doesn't tell us much about the effectiveness of any agent vs. placebo but only against each other. In other words, these drugs are either equally effective or equally ineffective. Furthermore, it is important to realize that hemodynamic parameters do not necessarily correlate with tissue perfusion and patient outcomes. It has not been proven that hemodynamic improvement in CS patients results in better outcome. Currently, CS is a clinical diagnosis that has not been well defined, and there is significant heterogeneity in CS definition among the studies used for meta-analysis. Therefore, the current level of evidence is insufficient to draw conclusions on whether vasopressors/inotropes are effective. However, we do believe it is of clinical importance to review and summarize the current evidence regarding routinely used therapies. This systematic review and meta-analysis is the first to report outcomes of commonly used vasopressor/inotropic therapies in patients with CS complicating AMI.

The authors believe that rigorous studies exploring the efficacy of vasopressors and inotropes with appropriate endpoint and methodology are advocated. Not only to compare the efficacy between different drugs and dosages but also to ascertain whether these drugs are effective in reducing mortality. Several RCTs that challenged the current pharmacological treatment in patients with out-of-hospital cardiac arrest (OHCA) demonstrated that although the administration of adrenaline was associated with improved short-term survival in OHCA, it did not affect survival with favorable neurological outcome \[[@B36-jcm-09-02051],[@B37-jcm-09-02051],[@B38-jcm-09-02051]\]. It is important to also initiate large placebo-controlled, double-blind, RCTs in CS patients to definitively establish the effect of pharmacological therapy. Studying the CS population in an RCT is challenging but feasible with the adoption of adequate methodology and statistical plan analysis.

In the present study, several decisions were made by the research team that could possibly limit our conclusion. The aim of this study was to summarize the evidence regarding vasopressor and inotropic treatment of a selected patient group (AMI related CS), since patients presenting with a non-hypotensive low-output status differ significantly in their treatment goal and strategy. Due to the limited number of studies exclusively reporting on patients with AMI related CS, we also included studies with mixed etiologies, as long as there were AMI patients included in the cohort.

Another limitation of our review was that the included studies were very heterogeneous in terms of participants, interventions, comparisons and outcomes. Specific subgroup analysis to reduce heterogeneity was not possible, due to the limited number of studies that were available regarding the different drugs. Moreover, single center, retrospective studies with a small sample size were included, which are likely to have significant selection bias. Furthermore, we included all study designs, without any publication or language restriction. It may be debatable to include conference papers (of which the methodological quality could not be properly assessed due to limited information). However, including conference papers may also reduce the effect of potential publication bias. Moreover, randomized evidence is very limited, and observational data is informative in assessing therapy-related complications and safety outcomes. To examine the best possible level of evidence, we performed sensitivity analyses where possible excluding the conference papers and/or observational studies.

5. Conclusions {#sec5-jcm-09-02051}
==============

There is insufficient evidence that routinely used vasopressors and inotropes are associated with reduced mortality in patients with AMI related CS. Considering the limited evidence, this study emphasizes the need for proper randomized trials.

The following are available online at <https://www.mdpi.com/2077-0383/9/7/2051/s1>. Table S1: Overall patient population and baseline characteristics. Table S2: Quality assessment of the randomized trials. Table S3: Quality assessment of the observational studies. Table S4: Mortality outcomes for cardiogenic shock population. Table S5: Primary and secondary outcome(s) of the included studies.
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572593

11

9 or 10 \[MI\]

737611

12

(\*shock/ or shock.ti.) not (exp heart stimulation/ or (septic or sepsis or bacter\*em\* or infect\* or endotoxin\* or heat shock or HSP\* or anaphyl\* or allergic or vasodilat\* or osmotic or h?emorr\* or bleeding or toxic or neurogen\* or burn\* or shock-wave or shock-resistant or hypovolemic or electroconvuls\* or distributive shock\*).ti.) \[shock general\]

32315

13

forward heart failure/

5518

14

((low\* or diminish\* or decreas\* or declin\* or reduc\* or negligibl\* or fall\*) adj2 (card\* or heart) adj output\*).tw,kw.

12569

15

((low\* or diminish\* or decreas\* or declin\* or reduc\* or negligibl\*) adj output\*).tw,kw.

2964

16

cardiac output low.tw,kw,ot.

105

17

(LCOS or COS or LCO).tw,ot,kw.

20242

18

((instab\* or unstab\*) adj1 h?emodyn\*).tw,kw.

12677

19

or/12-18 \[shock, low CO\]

81903

20

11 and 19 \[ II = MI + CO \]

10001

21

8 or 20 \[I II\]

38501

22

(book or editorial).pt. or book/ or editorial/ or (((\"review\" or letter).pt. or \"review\"/ or letter/) not (meta analysis/ or \"systematic review\"/ or clinical study/ or case control study/ or exp controlled clinical trial/ or controlled study/ or intervention study/ or longitudinal study/ or major clinical study/ or prospective study/ or retrospective study/ or cohort analysis/ or (systematic adj2 (literature or review)).tw,ot,kw.))

3896039

23

((animal/ or animal experiment/ or animal model/ or nonhuman/) not human/) or (porcine or piglet or pig or pigs or rat or rats or dogs or dog or canine).ti. or ph?eochrom\*.mp.

6420601

24

22 or 23

10059750

25

21 not 24 \[I II - humans not editorials, reviews\]

30861

26

\*inotropic agent/ or inotropic agent/ae, ct, cb, cm, dt

6390

27

\*cardiotonic agent/ or cardiotonic agent/ae, ct, cb, cm, dt

2726

28

catecholamine/ae, ct, cb, cm, dt

1671

29

(cardiotonic\* or inopressor\* or inodilator\*).tw,ot,kw.

3739

30

(catecholamines or inotropes or vasopressors or ((catecholamine or inotrop\* or vasopressor) adj3 (support or solution\* or infusion\* or dosing or dose\* or dosage\* or prescri\* or \"use\" or therap\* or treat\* or cotreat\* or administ\* or requir\* or need\* or superior or first-line or \"add\" or added or addition or adding or receiv\* or receipt or regimen\* or alone or combin\* or plus or compar\* or vs or versus or assigned or allocat\* or randomi?ed or effectiveness or efficacy or drug\* or agent\* or substance\* or group))).tw,ot,kw.

74053

31

dopamine/ not (dopamine/ec not dopamine/ae, cb, cm, dt)

80557

32

(dopamin\* or hydroxytyramin\* or Intropin\*).tw,ot,kw.

189228

33

dobutamine/ not (dobutamine/ec not dobutamine/ae, cb, cm, dt)

23435

34

dobutamin\*.tw,ot,kw.

12411

35

noradrenalin/ not (noradrenalin/ec not noradrenalin/ae, cb, cm, dt)

114540

36

(norepinephrin\* or noradrenalin\*).tw,ot,kw.

120459

37

adrenalin/ not (adrenalin/ec not adrenalin/ae, cb, cm, dt)

111164

38

(epinephrin\* or adrenalin\*).tw,ot,kw.

83979

39

milrinone/

7278

40

milrinon\*.tw,ot,kw.

2706

41

vasopressin/ not (vasopressin/ec not vasopressin/ad, cb, cm, dt)

29150

42

vasopressin\*.tw,ot,kw.

41607

43

simendan/

106

44

(simendan or levosimend\*).tw,ot,kw.

2165

45

or/26-44 \[drugs\]

549646

46

25 and 45 \[total\]

5721

47

remove duplicates from 46 \[total hits -deduplicated\]

5640

48

(embase or elsevier or canadian).cr.

26116001

49

47 and 48 \[ EMBASE records only\]

5261

**CENTRAL**

ID

Search

Hits

\#1

(cardiogen\* near/9 shock\*):ti,ab,kw

914

\#2

(circulator\* near/3 shock\*):ti,ab,kw

36

\#3

(coron\* NEXT shock\*):ti,ab,kw

0

\#4

(acute NEXT circulatory NEXT fail\*):ti,ab,kw

14

\#5

((undifferent\* or undiagnos\* or different or various or variety or type or types or kind or kinds or forms or states or etiologies) near/2 shock\*):ti,ab not (heat NEXT shock\*):ti,ab

82

\#6

\#1 or \#2 or \#3 or \#4 or \#5

1036

\#7

(((myocard\* or heart or card\* or ST) near/3 (infarct\* or isch\*em\*)) or ((coronary NEXT intervent\*) or STEMI or PCI or angioplast\* or (post NEXT isch\*) or postisch\* or postinfarct\* or (post NEXT infarct\*) or MI or AMI or (myocard\* NEXT revasc\*) or (coronary NEXT artery NEXT bypass\*) or CABG or (aortocoronary NEXT bypass\*) or (coronary NEXT bypass\*)))

57969

\#8

shock:ti,kw not (septic or sepsis or bacter\*em\* or infect\* or endotoxin\* or (heat NEXT shock) or HSP\* or anaphyl\* or allergic or vasodilat\* or osmotic or h\*emorr\* or bleeding or toxic or neurogen\* or burn\* or (shock NEXT wave) or (shock NEXT resistant) or hypovolemic or (hypo NEXT volemic) or electroconvuls\* or (distributive NEXT shock\*)):ti

2559

\#9

((low\* or diminish\* or decreas\* or declin\* or reduc\* or negligibl\* or fall\*) near/2 ((card\* NEXT output) OR (heart NEXT output))):ti,ab,kw

1094

\#10

((low\* or diminish\* or decreas\* or declin\* or reduc\* or negligibl\*) next output\*):ti,ab,kw

138

\#11

(LCOS or COS or LCO):ti,ab,kw

312

\#12

((instab\* or unstab\*) near/1 h\*emodyn\*):ti,ab,kw

633

\#13

\#8 or \#9 or \#10 \#11 or \#12

4238

\#14

\#7 and \#13

1078

\#15

\#6 or \#14

1595

\#16

(cardiotonic\* or inopressor\* or inodilator\* or dopamin\* or hydroxytyramin\* or Intropin\* or dobutamin\* or norepinephrin\* or noradrenalin\* or epinephrin\* or adrenalin\* or milrinon\* or vasopressin\* or simendan or levosimend\*):ti,ab,kw

22220

\#17

(catecholamines or inotropes or vasopressors or ((catecholamine or inotrop\* or vasopressor) near/3 (support or solution\* or infusion\* or dosing or dose\* or dosage\* or prescri\* or \"use\" or therap\* or treat\* or cotreat\* or administ\* or requir\* or need\* or superior or (first NEXT line) or \"add\" or added or addition or adding or receiv\* or receipt or regimen\* or alone or combin\* or plus or compar\* or vs or versus or assigned or allocat\* or randomi\*ed or effectiveness or efficacy or drug\* or agent\* or substance\* or group))):ti,ab,kw

4646

\#18

\#16 or \#17

24628

\#19

\#15 and \#18

277

![Flowchart of study selection.](jcm-09-02051-g001){#jcm-09-02051-f001}

![Forest plot demonstrating short-term (\<90 day) mortality of cardiogenic shock patients treated with a vasopressor/inotrope versus a constructed control group.](jcm-09-02051-g002){#jcm-09-02051-f002}

![Forest plot demonstrating long-term (≥90 day) mortality of cardiogenic shock patients treated with a vasopressor/inotrope versus a constructed control group.](jcm-09-02051-g003){#jcm-09-02051-f003}

jcm-09-02051-t001_Table 1

###### 

Summary of included studies (*n* = 19) on inotrope/vasopressor therapy in cardiogenic shock.

  Study         Year   Country     Center   Setting                                   Inclusion Period   Follow-up            Overall N   CS N
  ------------- ------ ----------- -------- ----------------------------------------- ------------------ -------------------- ----------- ------
  Cronin        1965   Canada      Single   Retrospective cohort                      1952--1961         10 years             140         140
  Moulopoulos   1993   Greece      Single   Retrospective cohort                      1978--1991         1 month              55          55
  Andriange     1971   Belgium     Single   Retrospective cohort                      1967--1970         1 year               450         45
  Samimi-Fard   2007   Spain       Single   Randomized trial                          2003--2004         1 year               22          22
  El Mokhtari   2007   Germany     Single   Retrospective cohort                      \-                 1 year               20          20
  Fuhrmann      2008   Germany     Single   Randomized trial                          2003--2005         30 days              32          32
  Myburgh       2008   Australia   Multi    Randomized trial                          2004--2006         90 days              280         128
  Christoph     2008   Germany     Single   Prospective cohort                        2003--2005         \-                   22          22
  De Backer     2010   Belgium     Multi    Randomized trial                          2003--2007         1 year               1679        280
  Omerovic      2010   Sweden      Single   Prospective cohort                        2004--2006         1 year               94          94
  Caetano       2012   Portugal    \-       Retrospective cohort (conference paper)   \-                 10.6 ± 10.9 months   37          37
  Huseby        2013   Norway      Single   Randomized trial                          2006--2010         6 months             61          9
  Affronti      2013   Italy       Single   Retrospective case-control                2011               \-                   17          17
  Katsytadze    2013   Ukraine     \-       Retrospective cohort (conference paper)   \-                 1 year               27          27
  Yagi          2015   Japan       Multi    Prospective cohort (conference paper)     2012--2014         30 days              979         240
  Tarvasmaki    2016   Finland     Multi    Prospective cohort                        2010--2012         90 days              216         216
  Levy          2018   France      Multi    Randomized trial                          2011--2016         60 days              57          57
  Vally         2019   France      Single   Retrospective cohort                      2010--2017         30 days              150         150
  Lewis         2018   USA         Single   Retrospective cohort                      2013--2015         In-hospital          100         100

CS: cardiogenic shock.

[^1]: These two authors contributed equally.
